20 completed, 13 unknown, 11 recruiting, 5 terminated. 57 Phase 2, 8 Phase 1, 4 Phase 3.
Follow Hypopharyngeal Neoplasms: new trials by email Literature Review of Hypopharyngeal Neoplasms trials Research Report on Hypopharyngeal Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2026-11-04 | 2026-10-30 |
| Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa - Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Washington University School of Medicine | 45 | 2026-09-30 | 2026-08-13 |
| Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma Finolizumab, Albumin-Bound Paclitaxel /nab-Paclitaxel, Cisplatin - Hypopharyngeal Carcinoma | Phase 2 | Recruiting | Eye & ENT Hospital of Fudan University | 116 | 2025-12-22 | 2025-12-23 |
| Neoadjuvant Treatment of Locally Advanced Hypopharyngeal Cancer With Adebrelimab Combined With TP Chemotherapy Regimen Adebrelimab+Albumin paclitaxel +Cisplatin - Locally Advanced Hypopharyngeal Cancer | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Xiamen University | 34 | 2025-08-20 | 2025-08-22 |
| Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population Celecoxib, Erlotinib Hydrochloride, Imaging Procedure - Metastatic Oral Cavity Carcinoma, Recurrent Oral Cavity Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 25 | 2025-08-07 | 2026-10-01 |
| A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) Sacituzumab Govitecan, Cetuximab - Squamous Cell Carcinoma of Head and Neck, Sinus Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 40 | 2025-07-02 | 2026-02-19 |
| Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer Best Practice, Biospecimen Collection, Cisplatin - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | NRG Oncology | 98 | 2025-06-23 | 2026-08-17 |
| Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial Biospecimen Collection, Computed Tomography, Lovastatin - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown Primary | Phase 2 | Recruiting | Emory University | 28 | 2024-12-09 | 2026-02-11 |
| SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx SBRT+Toripalimab Plus Docetaxel and Cisplatin - Laryngeal Cancer, Hypopharynx Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 35 | 2024-09-11 | 2024-09-26 |
| Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer chemotherapy TP regimen combined with Tislelizumab - Laryngeal Cancer, Hypopharynx Cancer | Phase 2 | Not yet recruiting | Henan Cancer Hospital | 46 | 2024-08-01 | 2024-08-14 |
| Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer Biospecimen Collection, Carboplatin, Chest Radiography - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Withdrawn | ECOG-ACRIN Cancer Research Group | 2024-04-12 | 2024-07-25 | |
| Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer Surgery, Radiation, Toripalimab - Larynx Cancer, Hypopharyngeal Cancer | Phase 2 | Recruiting | Fudan University | 82 | 2023-08-22 | 2023-09-15 |
| Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers Atezolizumab, Bevacizumab, Biospecimen Collection - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 430 | 2023-03-13 | 2026-10-01 |
| BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 150 | 2022-12-06 | 2026-10-29 |
| Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Biopsy Procedure, Biospecimen Collection, Computed Tomography - Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 52 | 2022-07-26 | 2026-09-21 |
| Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study Cisplatin, Intensity-Modulated Proton Therapy, Quality-of-Life Assessment - Head and Neck Carcinoma, Head and Neck Carcinoma of Unknown Primary | Phase 2 | Active not recruiting | Mayo Clinic | 174 | 2022-02-16 | 2026-07-16 |
| Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Carboplatin, Cemiplimab, Paclitaxel - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Marcelo Bonomi | 46 | 2021-11-30 | 2026-06-25 |
| Efficacy and Safety of Toripalimab Combined With AP-induced Chemotherapy Followed in Non-metastatic IVB Hypopharyngeal Cancer Cisplatin/Nedaplatin, albumin paclitaxel - Hypopharyngeal Cancer | Phase 2 | Unknown | Chinese PLA General Hospital | 30 | 2021-07-01 | 2024-02-20 |
| Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma Toripalimab - Laryngeal Cancer, Hypopharyngeal Cancer | Phase 2 | Unknown | Fudan University | 61 | 2021-04-07 | 2022-06-15 |
| Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma chemotherapy TP regimen combined with Toripalimab - Laryngeal Cancer, Hypopharynx Cancer | Phase 2 | Unknown | Fudan University | 42 | 2021-04-07 | 2022-01-18 |
Showing 20 of 57. Sign in to see all of them.
Laryngeal Neoplasms (44) · Mouth Neoplasms (36) · Oropharyngeal Neoplasms (35) · Head and Neck Neoplasms (22) · Squamous Cell Carcinoma of Head and Neck (22) · Nasopharyngeal Neoplasms (16) · Carcinoma (13) · Salivary Gland Neoplasms (11) · Tongue Neoplasms (8) · Carcinoma, Non-Small-Cell Lung (6) · Paranasal Sinus Neoplasms (6) · Carcinoma, Renal Cell (5) · Esophageal Neoplasms (5) · Nasopharyngeal Carcinoma (4)
Otorhinolaryngologic Diseases (57) · Otorhinolaryngologic Neoplasms (57) · Pharyngeal Diseases (57) · Pharyngeal Neoplasms (57) · Stomatognathic Diseases (57) · Neoplasms by Site (56) · Neoplasms (55) · Respiratory Tract Diseases (45) · Respiratory Tract Neoplasms (45) · Laryngeal Diseases (44) · Mouth Diseases (37) · Head and Neck Neoplasms (35) · Neoplasms by Histologic Type (29) · Neoplasms, Glandular and Epithelial (29) · Carcinoma, Squamous Cell (20)
Cisplatin (18) · Cetuximab (8) · Specimen Handling (7) · 1,2-diaminocyclohexaneplatinum II citrate (6) · Magnetic Resonance Spectroscopy (6) · Radiotherapy (6) · Radiotherapy, Intensity-Modulated (6) · Docetaxel (5) · Platinum (5) · Surgical Procedures, Operative (5) · pembrolizumab (5) · Celecoxib (4) · Fluorouracil (4) · Paclitaxel (4) · toripalimab (4)
National Cancer Institute (NCI) (5) · Fudan University (3) · Mayo Clinic (3) · ECOG-ACRIN Cancer Research Group (2) · Eye & ENT Hospital of Fudan University (2) · Memorial Sloan Kettering Cancer Center (2) · Roswell Park Cancer Institute (2) · Sun Yat-sen University (2) · Abramson Cancer Center at Penn Medicine (1) · Burzynski Research Institute (1) · Chinese Academy of Medical Sciences (1) · Chinese PLA General Hospital (1) · Dana-Farber Cancer Institute (1) · Emory University (1) · Fox Chase Cancer Center (1)
United States (36) · China (13) · Canada (3) · France (2) · South Korea (2) · Switzerland (2) · Germany (1) · Singapore (1) · Taiwan (1)
Everett E. Vokes, MD (2) · Xiayun He, M.D. (2) · Yu Wang, M.D. (2) · Aarti Bhatia (1) · Amit Agrawal (1) · Arlene A. Forastiere, MD (1) · Assuntina Sacco, M.D. (1) · C. Jillian Tsai, MD (1) · Charalampos Floudas, M.D. (1) · Chunmei Bai (1) · David M Brizel (1) · Fred R. Rosen, MD (1) · Gary G. Schwartz, MD, PhD, MPH (1) · Heath D Skinner (1)
PMID 16849759, PMID 21831465, PMID 22252927, PMID 23341517, PMID 25965900, PMID 26062933, PMID 26611425, PMID 29346519, PMID 30850872, PMID 31705729, PMID 33989559, PMID 36447152, PMID 39551064, PMID 40404202, PMID 42498484
U10CA180820 (3), P30CA006516 (1), P30CA006973 (1), P30CA015083 (1), P30CA042014 (1), P30CA138292 (1), P50CA096784 (1), U10CA180868 (1), U10CA180888 (1), UG1CA189867 (1), UM1CA186717 (1)